Muhammad Mukhlis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Muhammad Mukhlis has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Kaneez Fatima
CMH Institute of Medical Science, Multan, Pakistan
4 shared publications - Sadia Qazi
College of Medicine, Alfaisal University
4 shared publications - Vishan Das
Liaquat University of Medical & Health Sciences, Jamshoro, Pakistan
4 shared publications - Akef Obeidat
Department of Anatomy, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia
3 shared publications - Eshal Atif
College of Medicine, Alfaisal University, Riyadh, Saudi Arabia
3 shared publications - Muhammad Atif Mazhar
Department of Anatomy, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia
3 shared publications
Latest Publications
- Open Access
- 16 October 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (42) , e51146
Trends and projections of colorectal carcinoma mortality in U.S. adults, 1999–2050
Colorectal carcinoma (CRC) remains a major cause of cancer mortality in the United States (U.S.); however, contemporary long-term projections by demographic and geographic strata are limited. This study examined national colorectal cancer mortality trends from 1999 to 2025 and projected age-adjusted mortality rates (AAMRs) through 2050. We conducted an ecological time-series analysis of U.S. adults aged ≥ 25 years using Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research Multiple Cause of Death data. CRC-related deaths were identified by any mention of International Classification of Diseases, Tenth Revision codes C18–C20 on the death certificate. AAMRs per 100,000 population were calculated overall and stratified by sex, age group, race and ethnicity, urbanization, census region, state, and place of death. Joinpoint regression was used to estimate the annual percent change and average annual percent change. A demographically optimized ensemble forecasting model was used to project AAMRs from 2026 to 2050. From 1999 to 2025, 1,674,393 CRC-related deaths were recorded. Overall, the AAMR declined from 38.11 in 1999 to 23.14 in 2025 (average annual percent change, −1.99%; 95% confidence interval, −2.13 to −1.85; P < .001), but recent rates have stabilized. The mean AAMR was higher among men than women (34.13 vs 23.43) and higher in nonmetropolitan than metropolitan areas (32.43 vs 28.49). Non-Hispanic Black adults had the highest racial and ethnic burdens (37.45). Adults aged 25 to 44 years showed a significant increase in mortality (annual percent change, 1.13%; 95% confidence interval, 0.93 to 1.33; P < .001). Most deaths occurred at home (41.15% of deaths). The overall AAMR was projected to continue declining slowly, from 23.02 in 2026 to 21.56 in 2050, at a slower pace than the 1999 to 2016 decline. U.S. CRC mortality has declined substantially and is projected to continue declining slowly through 2050, rather than resume its earlier faster decline, with persistent sex, racial, rural, age, and geographic disparities. Targeted strategies are needed to improve screening completion, diagnostic follow-up, rural access, equity, and early-onset colorectal cancer detection.
- 16 October 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (42) , e51146
Open AccessTrends and projections of colorectal carcinoma mortality in U.S. adults, 1999–2050
Colorectal carcinoma (CRC) remains a major cause of cancer mortality in the United States (U.S.); however, contemporary long-term projections by demographic and geographic strata are limited. This study examined national colorectal cancer mortality trends from 1999 to 2025 and projected age-adjusted mortality rates (AAMRs) through 2050. We conducted an ecological time-series analysis of U.S. adults aged ≥ 25 years using Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research Multiple Cause of Death data. CRC-related deaths were identified by any mention of International Classification of Diseases, Tenth Revision codes C18–C20 on the death certificate. AAMRs per 100,000 population were calculated overall and stratified by sex, age group, race and ethnicity, urbanization, census region, state, and place of death. Joinpoint regression was used to estimate the annual percent change and average annual percent change. A demographically optimized ensemble forecasting model was used to project AAMRs from 2026 to 2050. From 1999 to 2025, 1,674,393 CRC-related deaths were recorded. Overall, the AAMR declined from 38.11 in 1999 to 23.14 in 2025 (average annual percent change, −1.99%; 95% confidence interval, −2.13 to −1.85; P < .001), but recent rates have stabilized. The mean AAMR was higher among men than women (34.13 vs 23.43) and higher in nonmetropolitan than metropolitan areas (32.43 vs 28.49). Non-Hispanic Black adults had the highest racial and ethnic burdens (37.45). Adults aged 25 to 44 years showed a significant increase in mortality (annual percent change, 1.13%; 95% confidence interval, 0.93 to 1.33; P < .001). Most deaths occurred at home (41.15% of deaths). The overall AAMR was projected to continue declining slowly, from 23.02 in 2026 to 21.56 in 2050, at a slower pace than the 1999 to 2016 decline. U.S. CRC mortality has declined substantially and is projected to continue declining slowly through 2050, rather than resume its earlier faster decline, with persistent sex, racial, rural, age, and geographic disparities. Targeted strategies are needed to improve screening completion, diagnostic follow-up, rural access, equity, and early-onset colorectal cancer detection.
- Open Access
- 8 October 2026
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 9 (6) , e70355
Impact of Evolocumab on LDL‐Cholesterol and Cardiovascular Outcomes in Patients With Established CVD: Systematic Review and Meta‐Analysis
Background: Atherosclerotic cardiovascular disease is a leading cause of morbidity and mortality, and many high‐risk patients fail to reach LDL‐cholesterol (LDL‐C) targets on statins alone. Evolocumab, a PCSK9 inhibitor, offers potent LDL‐C lowering, but a synthesis of its lipid and clinical benefits in secondary prevention is needed. Methods: We conducted a systematic review and meta‐analysis of randomised controlled trials evaluating evolocumab in adults with established cardiovascular disease. PubMed, Embase, Scopus, Cochrane CENTRAL, and ClinicalTrials.gov were searched through April 2025. Outcomes included lipid parameters, major adverse cardiovascular events (MACE), individual cardiovascular endpoints, and safety, with pooled risk ratios (RR) and mean differences calculated using random‐effects models. Results: Nine trials enrolling 67,662 patients were included. Evolocumab significantly reduced LDL‐C (mean difference −57.73 mg/dL), total cholesterol (−52.27 mg/dL), triglycerides (−21.21 mg/dL), and lipoprotein(a) (−10.99 mg/dL), while increasing HDL‐cholesterol (3.69 mg/dL). Evolocumab was associated with lower MACE (RR 0.53; 95% CI 0.40–0.71), though this estimate should be interpreted cautiously given heterogeneity in endpoint definitions and study designs. Myocardial infarction (RR 0.74) and coronary revascularisation (RR 0.80) were significantly reduced, while cardiovascular mortality and stroke showed no statistically definitive reduction. Serious adverse events and neurocognitive effects were comparable between groups, though injection‐site reactions were more frequent with evolocumab. Conclusion: In patients with established cardiovascular disease, evolocumab provides substantial lipid lowering and reduces ischemic events without major safety concerns, supporting its use as an adjunct to statin therapy in secondary prevention.
- 8 October 2026
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 9 (6) , e70355
Open AccessImpact of Evolocumab on LDL‐Cholesterol and Cardiovascular Outcomes in Patients With Established CVD: Systematic Review and Meta‐Analysis
Background: Atherosclerotic cardiovascular disease is a leading cause of morbidity and mortality, and many high‐risk patients fail to reach LDL‐cholesterol (LDL‐C) targets on statins alone. Evolocumab, a PCSK9 inhibitor, offers potent LDL‐C lowering, but a synthesis of its lipid and clinical benefits in secondary prevention is needed. Methods: We conducted a systematic review and meta‐analysis of randomised controlled trials evaluating evolocumab in adults with established cardiovascular disease. PubMed, Embase, Scopus, Cochrane CENTRAL, and ClinicalTrials.gov were searched through April 2025. Outcomes included lipid parameters, major adverse cardiovascular events (MACE), individual cardiovascular endpoints, and safety, with pooled risk ratios (RR) and mean differences calculated using random‐effects models. Results: Nine trials enrolling 67,662 patients were included. Evolocumab significantly reduced LDL‐C (mean difference −57.73 mg/dL), total cholesterol (−52.27 mg/dL), triglycerides (−21.21 mg/dL), and lipoprotein(a) (−10.99 mg/dL), while increasing HDL‐cholesterol (3.69 mg/dL). Evolocumab was associated with lower MACE (RR 0.53; 95% CI 0.40–0.71), though this estimate should be interpreted cautiously given heterogeneity in endpoint definitions and study designs. Myocardial infarction (RR 0.74) and coronary revascularisation (RR 0.80) were significantly reduced, while cardiovascular mortality and stroke showed no statistically definitive reduction. Serious adverse events and neurocognitive effects were comparable between groups, though injection‐site reactions were more frequent with evolocumab. Conclusion: In patients with established cardiovascular disease, evolocumab provides substantial lipid lowering and reduces ischemic events without major safety concerns, supporting its use as an adjunct to statin therapy in secondary prevention.
- Open Access
- 8 October 2026
- Published by Springer Nature in BMC Pulmonary Medicine
Temporal trends in mortality associated with chronic lower respiratory disease and dementia: evidence from CDC WONDER, 1999–2023
Introduction: Chronic lower respiratory disease (CLRD) and dementia are the leading causes of death among older US adults and frequently coexist; however, their combined mortality burden is uncharacterized nationally. We examined the trends and disparities in deaths involving both. Methods: We analyzed 1999–2023 US multiple cause-of-death data from the CDC WONDER for decedents aged ≥ 65 years with both CLRD (ICD-10 J40–J47) and dementia (F01, F03, G30–G31) listed anywhere on the certificate. Age-adjusted mortality rates (AAMRs) per 100,000 were calculated overall and by sex, race/ethnicity, census region, urbanization, and place of death; crude rates (CMRs) were used for age strata. Joinpoint regression gave annual and average annual percent changes (APCs, AAPCs). Results: Among 557,547 deaths, the overall AAMR rose from 29.50 per 100,000 in 1999 to 55.69 in 2023, peaking at 65.70 in 2020 (AAPC: 2.64; 95% CI: 0.93–4.39; p = 0.002). Men had a higher mean AAMR than women (57.58 vs. 47.29), but only women rose significantly (AAPC: 3.66; p < 0.001 vs. 1.42; p = 0.128); the male-to-female ratio fell from 1.62 to 0.97, with women overtaking men by 2023. The mean AAMRs were 55.07 in non-Hispanic (NH) White (AAPC: 3.02; p = 0.0004), 40.56 in NH Black (2.70; p = 0.035), 32.47 in Hispanic (1.20; p = 0.001), and 20.42 in NH Asian or Pacific Islander adults (3.13; p = 0.206); and 55.18 in the South (2.80; p < 0.001), 54.84 in the Midwest (3.02; p = 0.004), 51.19 in the West (2.53; p = 0.005), and 39.60 in the Northeast (1.91; p = 0.065). Non-metropolitan AAMRs exceeded metropolitan AAMRs (61.70 vs. 47.61; AAPC: 4.12; p < 0.001 vs. 2.85; p = 0.008), with the gap widening from 5.0 to 22.6. 2023 CMRs were 243.83 (≥ 85 years; AAPC: 3.19; p = 0.001), 59.36 (75–84; 2.38; p = 0.011) and 8.98 (65–74; 2.80; p = 0.019). Nursing home deaths fell from 58.2% to 43.3% as home deaths rose to 28.0% and hospice deaths to 7.9%. Conclusion: Mortality involving coexisting CLRD and dementia in older US adults nearly doubled from 1999 to 2023, shifting toward women, non-metropolitan residents, and the very old, while end-of-life care moved from hospitals and nursing homes into homes and hospices.
- 8 October 2026
- Published by Springer Nature in BMC Pulmonary Medicine
Open AccessTemporal trends in mortality associated with chronic lower respiratory disease and dementia: evidence from CDC WONDER, 1999–2023
Introduction: Chronic lower respiratory disease (CLRD) and dementia are the leading causes of death among older US adults and frequently coexist; however, their combined mortality burden is uncharacterized nationally. We examined the trends and disparities in deaths involving both. Methods: We analyzed 1999–2023 US multiple cause-of-death data from the CDC WONDER for decedents aged ≥ 65 years with both CLRD (ICD-10 J40–J47) and dementia (F01, F03, G30–G31) listed anywhere on the certificate. Age-adjusted mortality rates (AAMRs) per 100,000 were calculated overall and by sex, race/ethnicity, census region, urbanization, and place of death; crude rates (CMRs) were used for age strata. Joinpoint regression gave annual and average annual percent changes (APCs, AAPCs). Results: Among 557,547 deaths, the overall AAMR rose from 29.50 per 100,000 in 1999 to 55.69 in 2023, peaking at 65.70 in 2020 (AAPC: 2.64; 95% CI: 0.93–4.39; p = 0.002). Men had a higher mean AAMR than women (57.58 vs. 47.29), but only women rose significantly (AAPC: 3.66; p < 0.001 vs. 1.42; p = 0.128); the male-to-female ratio fell from 1.62 to 0.97, with women overtaking men by 2023. The mean AAMRs were 55.07 in non-Hispanic (NH) White (AAPC: 3.02; p = 0.0004), 40.56 in NH Black (2.70; p = 0.035), 32.47 in Hispanic (1.20; p = 0.001), and 20.42 in NH Asian or Pacific Islander adults (3.13; p = 0.206); and 55.18 in the South (2.80; p < 0.001), 54.84 in the Midwest (3.02; p = 0.004), 51.19 in the West (2.53; p = 0.005), and 39.60 in the Northeast (1.91; p = 0.065). Non-metropolitan AAMRs exceeded metropolitan AAMRs (61.70 vs. 47.61; AAPC: 4.12; p < 0.001 vs. 2.85; p = 0.008), with the gap widening from 5.0 to 22.6. 2023 CMRs were 243.83 (≥ 85 years; AAPC: 3.19; p = 0.001), 59.36 (75–84; 2.38; p = 0.011) and 8.98 (65–74; 2.80; p = 0.019). Nursing home deaths fell from 58.2% to 43.3% as home deaths rose to 28.0% and hospice deaths to 7.9%. Conclusion: Mortality involving coexisting CLRD and dementia in older US adults nearly doubled from 1999 to 2023, shifting toward women, non-metropolitan residents, and the very old, while end-of-life care moved from hospitals and nursing homes into homes and hospices.
- Open Access
- 13 August 2026
- Published by Springer Nature in BMC Gastroenterology
- Vol. 26 (1)
Temporal trends and demographic disparities in constipation-associated mortality in the United States, 1999–2024
- 13 August 2026
- Published by Springer Nature in BMC Gastroenterology
- Vol. 26 (1)
Open AccessTemporal trends and demographic disparities in constipation-associated mortality in the United States, 1999–2024
- Open Access
- 9 June 2026
- Published by Elsevier in SSRN Electronic Journal
National Trends in Mortality Involving Coronary Artery Disease and Depression in the United States, 1999–2025: A CDC WONDER Analysis
Background: Coronary artery disease (CAD) and depression frequently coexist and may synergistically worsen outcomes through behavioral, inflammatory, and neuroendocrine mechanisms. However, national mortality trends involving both conditions remain incompletely characterized.Objective: To evaluate temporal trends and demographic disparities in mortality involving CAD and depression in the United States from 1999–2025.Methods: We conducted a retrospective population-based study using the CDC WONDER Multiple Cause of Death database. Adults aged ≥25 years with ICD-10 codes for CAD (I20–I25) and depression (F32, F33, F41.2) listed anywhere on the death certificate were identified. Age-adjusted mortality rates (AAMRs) per 100,000 population were standardized to the 2000 U.S. population. Joinpoint regression was used to estimate annual percent change (APC) and average annual percent change (AAPC), with analyses stratified by age, sex, race/ethnicity, geographic region, urbanization, and state.Results: A total of 85,806 deaths were identified, with an overall average AAMR of 1.42. Mortality declined from 1.81 (95% CI, 1.75–1.87) in 1999 to 1.31 (95% CI, 1.26–1.35) in 2025 (AAPC, −1.38; p=0.002), although rates increased significantly between 2017 and 2020. Mortality was highest among older adults but increased among middle-aged adults (AAPC, 1.10; p<0.001). Males had higher mortality than females. The Midwest had the highest regional burden, while the South showed no significant overall improvement. Mortality increased among Black individuals after 2014 and remained higher in nonmetropolitan areas.Conclusions: Mortality involving CAD and depression declined overall but remained heterogeneous, with persistent racial and geographic disparities and rising mortality among middle-aged adults.
- 9 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessNational Trends in Mortality Involving Coronary Artery Disease and Depression in the United States, 1999–2025: A CDC WONDER Analysis
Background: Coronary artery disease (CAD) and depression frequently coexist and may synergistically worsen outcomes through behavioral, inflammatory, and neuroendocrine mechanisms. However, national mortality trends involving both conditions remain incompletely characterized.Objective: To evaluate temporal trends and demographic disparities in mortality involving CAD and depression in the United States from 1999–2025.Methods: We conducted a retrospective population-based study using the CDC WONDER Multiple Cause of Death database. Adults aged ≥25 years with ICD-10 codes for CAD (I20–I25) and depression (F32, F33, F41.2) listed anywhere on the death certificate were identified. Age-adjusted mortality rates (AAMRs) per 100,000 population were standardized to the 2000 U.S. population. Joinpoint regression was used to estimate annual percent change (APC) and average annual percent change (AAPC), with analyses stratified by age, sex, race/ethnicity, geographic region, urbanization, and state.Results: A total of 85,806 deaths were identified, with an overall average AAMR of 1.42. Mortality declined from 1.81 (95% CI, 1.75–1.87) in 1999 to 1.31 (95% CI, 1.26–1.35) in 2025 (AAPC, −1.38; p=0.002), although rates increased significantly between 2017 and 2020. Mortality was highest among older adults but increased among middle-aged adults (AAPC, 1.10; p<0.001). Males had higher mortality than females. The Midwest had the highest regional burden, while the South showed no significant overall improvement. Mortality increased among Black individuals after 2014 and remained higher in nonmetropolitan areas.Conclusions: Mortality involving CAD and depression declined overall but remained heterogeneous, with persistent racial and geographic disparities and rising mortality among middle-aged adults.
- 27 March 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 107 (6) , 2078-2097
Left Atrium and Mitral Valve Hemodynamics in Patients With Mitral Stenosis Pre and Post‐Percutaneous Balloon Mitral Valvuloplasty: A Systematic Review and Meta‐Analysis
Mitral stenosis (MS) is still a significant cause of cardiovascular morbidity and mortality in low‐ and middle‐income countries, despite being nearly eradicated in the developed world. Percutaneous balloon mitral valvuloplasty (PBMV) is the treatment of choice for appropriate patients with MS, but traditional predictors such as mitral valve area and regurgitation grade fail to fully reflect long‐term prognosis. This review aims to analyze pre‐ and post‐PBMV hemodynamic changes in the left atrium and determine their prognostic significance in predicting clinical outcomes in patients with MS. This meta‐analysis followed PRISMA guidelines and was registered in PROSPERO (CRD420251017356). PubMed, Scopus, and Web of Science were searched on March 23, 2025, for studies on adults ≥ 18 years with isolated MS undergoing PBMV. Eligible studies reported both pre‐ and post‐procedure valve and hemodynamic parameters. Primary outcomes included mitral valve area, mean gradient, and left atrial indices. Pooled analyses were conducted in R (v 4.5.1). This meta‐analysis included the outcomes of PBMV by comparing pre‐ and post‐procedural data from 30 studies consisting of 2239 participants. Post‐PBMV outcomes revealed a significant increase in mitral valve area (MD 0.8834, 95% CI: 0.80; 0.96, p < 0.0001), cardiac output (MD 0.70, 95% CI: 0.58; 0.81, p < 0.0001), and alongside significant reductions in left atrial diameter (MD −4.47; 95% CI: −6.23 to −2.71, p < 0.0001), left atrial pressure (MD −9.51, 95% CI: −11.19; −7.84, p < 0.0001), mitral valve pressure (MD −8.58, 95% CI: −9.41; −7.74, p < 0.0001), and systolic pulmonary pressure (MD −17.96, 95% CI: −21.48; −14.45, p < 0.0001). Out of 2239 patients, 71, 37, and 32 had valve replacement, PBMV repetition, and experienced death, respectively. PBMV showed promising effectiveness and safety in treating patients with MS with a significant increase in cardiac output and MV area and a significant decrease in LA diameter, LA pressure, MV pressure, and systolic pulmonary pressure post‐PBMV, while observing low adverse events.
- 27 March 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 107 (6) , 2078-2097
Left Atrium and Mitral Valve Hemodynamics in Patients With Mitral Stenosis Pre and Post‐Percutaneous Balloon Mitral Valvuloplasty: A Systematic Review and Meta‐Analysis
Mitral stenosis (MS) is still a significant cause of cardiovascular morbidity and mortality in low‐ and middle‐income countries, despite being nearly eradicated in the developed world. Percutaneous balloon mitral valvuloplasty (PBMV) is the treatment of choice for appropriate patients with MS, but traditional predictors such as mitral valve area and regurgitation grade fail to fully reflect long‐term prognosis. This review aims to analyze pre‐ and post‐PBMV hemodynamic changes in the left atrium and determine their prognostic significance in predicting clinical outcomes in patients with MS. This meta‐analysis followed PRISMA guidelines and was registered in PROSPERO (CRD420251017356). PubMed, Scopus, and Web of Science were searched on March 23, 2025, for studies on adults ≥ 18 years with isolated MS undergoing PBMV. Eligible studies reported both pre‐ and post‐procedure valve and hemodynamic parameters. Primary outcomes included mitral valve area, mean gradient, and left atrial indices. Pooled analyses were conducted in R (v 4.5.1). This meta‐analysis included the outcomes of PBMV by comparing pre‐ and post‐procedural data from 30 studies consisting of 2239 participants. Post‐PBMV outcomes revealed a significant increase in mitral valve area (MD 0.8834, 95% CI: 0.80; 0.96, p < 0.0001), cardiac output (MD 0.70, 95% CI: 0.58; 0.81, p < 0.0001), and alongside significant reductions in left atrial diameter (MD −4.47; 95% CI: −6.23 to −2.71, p < 0.0001), left atrial pressure (MD −9.51, 95% CI: −11.19; −7.84, p < 0.0001), mitral valve pressure (MD −8.58, 95% CI: −9.41; −7.74, p < 0.0001), and systolic pulmonary pressure (MD −17.96, 95% CI: −21.48; −14.45, p < 0.0001). Out of 2239 patients, 71, 37, and 32 had valve replacement, PBMV repetition, and experienced death, respectively. PBMV showed promising effectiveness and safety in treating patients with MS with a significant increase in cardiac output and MV area and a significant decrease in LA diameter, LA pressure, MV pressure, and systolic pulmonary pressure post‐PBMV, while observing low adverse events.